Nuvalent presents new data showing extensive preclinical activity of NVL-520 in ROS1-induced cancers


Nuvalent Inc. NUVL announced new data on NVL-520 and NVL-655, central nervous system (CNS) penetrating kinase inhibitors, at the American Association for Cancer Research (AACR) annual meeting.

  • NVL-520 shows high activity against various tested ROS1 fusion partners and induces regression in a ROS1-driven glioblastoma model harboring GOPC(L)-ROS1.
  • NVL-655 shows strong activity in various preclinical models of ALK-induced cancers, including cholangiocarcinoma, neuroblastoma, lymphoma, and soft tissue sarcoma.
  • NVL-655 exhibits activity for various ALK oncoproteins among all inhibitors tested, including fusions, point mutations, and partial N-terminal deletions.
  • NVL-520 is currently in the Phase 1 ARROS-1 Phase 1/2 study for advanced ROS1-positive NSCLC and other solid tumors.
  • Nuvalent recently announced IND clearance for NVL-655 and plans to initiate Phase 1 of the Phase 1/2 ALKOVE-1 study for advanced ALK-positive NSCLC and other solid tumors in the second quarter of 2022 .
  • Nuvalent is also advancing a discovery pipeline with plans to name two new development candidates in 2022 for ALK compound IXDN mutations and HER2 exon 20 insertions.
  • Price action: NUVL shares closed up 3.87% at $13.15 on Friday

About Author

Comments are closed.